Patents Assigned to Medical Prognosis Institute A/S
  • Methods for predicting drug responsiveness
    Patent number: 10570457
    Abstract: The present invention provides drug response predictors and biomarkers useful for assessing the responsiveness of a subject to treatment with one or more target drugs of interest, such as 5-fluorouracil (5-FU), irinotecan, and/or oxaliplatin. In particular, the invention provides methods useful in determining whether a subject is sensitive or resistant to a target drug by, e.g., measuring the expression level of one or more biomarkers of sensitivity and/or resistance to the drug in a biological sample obtained from the subject. The invention further features devices and kits for assessing target drug responsiveness in a subject, for example, by determining the expression level of such biomarkers.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: February 25, 2020
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
    Patent number: 10392667
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment, such as fulvestrant.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: August 27, 2019
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Methods and devices for predicting treatment efficacy
    Patent number: 9598734
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying biomarkers, the expression of which correlates to treatment sensitivity or resistance within a patient population or subpopulation.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: March 21, 2017
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE
    Publication number: 20140106986
    Abstract: The present invention features microRNAs as biomarkers for prognosing cancer relapse in cancer patient. The present invention also features methods, devices, and kits for this purpose.
    Type: Application
    Filed: June 1, 2012
    Publication date: April 17, 2014
    Applicant: Medical Prognosis Institute A/S
    Inventors: Steen Knudsen, Wiktor Mazin
  • Predictive Biomarkers for Response to Exercise
    Publication number: 20140094381
    Abstract: A set of biomarkers have been identified that allows one to predict subjects who will respond to an exercise regime in term of cardiorespiratory fitness as assessed by maximal oxygen uptake. These predictions may be used, for example, to predict risk of cardiovascular disease, to design a more effective program for cardiac rehabilitation, to predict capacity for athletic performance or physically demanding occupation, and to predict ability to maintain functional capacity with aging using exercise.
    Type: Application
    Filed: September 6, 2013
    Publication date: April 3, 2014
    Applicants: Medical Prognosis Institute A/S, Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: JAMES TIMMONS, STEEN KNUDSEN, TUOMO RANKINEN, CARL JOHAN SUNDBERG, CLAUDE BOUCHARD
  • METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY
    Publication number: 20130053275
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying biomarkers, the expression of which correlates to treatment sensitivity or resistance within a patient population or subpopulation.
    Type: Application
    Filed: April 29, 2011
    Publication date: February 28, 2013
    Applicant: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen